Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TLX
TELIX PHARMACEUTICALS LIMITED
NASDAQ
$11.29
▼ DOWN 0.75% (-0.09)

KEY STATISTICS

Market Cap$3.82 B
52w High$12.48
52w Low$6.28
Dividend Yield—
Frequency—
P/E117.85
Volume88.47K
Shares Out.338.78M

COMPANY

LEADERSHIP

Christian Behrenbruch
CHIEF EXECUTIVE
Christian Behrenbruch

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 14, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,152

PRICE TARGET

Target High$18.00
Target Low$18.00
Target Median$18.00
Target Consensus$18.00

UPCOMING EARNINGS

DateFeb 19, 2027
DayFriday
Rev. Est.$493.27M
FEB
19
FRI

PRICE

$11.29 ▼ DOWN 0.75% (−$0.09)
$11.25$11.30$11.359:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM11.29

About Telix Pharmaceuticals Limited

https://telixpharma.com ↗

Telix Pharmaceuticals is a global biopharmaceutical company developing and commercializing radiopharmaceuticals for cancer and rare diseases, with products and candidates targeting prostate, kidney, brain, and soft tissue cancers.

INDUSTRY

Biotechnology

A PRODUCT TELIX PHARMACEUTICALS LIMITED IS KNOWN FOR

Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection)
Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection)

Illuccix is Telix's leading radiopharmaceutical for PET imaging of PSMA-positive prostate cancer lesions, approved in multiple countries, enhancing diagnosis and treatment planning.

COMPETITORS

COMPETITOR
AZN COMPARE
LLY COMPARE
LNTH COMPARE
NVS COMPARE

Revenue by Products

IconPRODUCTQ1-2013Q3-2013Q2-2016Q2-2019
Digital Product Sales— — $5M $11.74M ▲
Digital Display— $4.61M — —
Digital Product Lease And Maintenance— — $776K $4M ▲
Digital Display Lease And Maintenance$1.65M $1.6M ▼— —

Revenue by Geography

MapREGIONFY2024FY2025
UNITED STATES$762.31M $784.9M ▲
CHINA— $9.83M
CANADA$2.54M —
AUSTRALIA$1.22M —
BELGIUM$546K —

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
6
RANKED BY POSITION SIZE
SCHF
0.03% · 136.0K
SPDW
0.03% · 77.3K
APIE
0.01% · 8.7K
IQIN
0.16% · 1.8K
DM
DMRI
0.01% · 553
IVSI
0.35% · 238

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.72%
HOLDERS
48
TOP 12 OF 48 · RANKED BY POSITION SIZE
Fmr LLC
564.8K sh · $5.4M
Portolan Capital Management, LLC
541.3K sh · $5.18M
Lazard Asset Management LLC
289.9K sh · $2.77M
Portland Investment Counsel Inc.
266.2K sh · $2.55M
Private Advisor Group, LLC
174.4K sh · $1.67M
Integrated Wealth Concepts LLC
164.4K sh · $1.57M
Raiffeisen Bank International AG
130.0K sh · $1.16M
Morgan Stanley
116.4K sh · $1.11M
Jpmorgan Chase & Co
74.4K sh · $557.02K
Marshall Wace, Llp
46.7K sh · $349.47K
Mariner, LLC
43.4K sh · $415.34K
Jane Street Group, LLC
40.0K sh · $299.92K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity3
Return On Assets4
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR:
Rivas Maria
— · —
2026-05-11
★
DIRECTOR:
Jellison William R
— · —
2026-05-11
★
DIRECTOR:
GILL DAVID N
— · —
2026-05-11
★
DIRECTOR, OFFICER: MD & GROUP CEO
Behrenbruch Christian
Purchase · 33.4K shares
2026-04-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Citigroup BUY HC Wainwright & Co. BUY UBS BUY

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
BLTE$151.72COMPARE
MIRM$97.46COMPARE
LGND$280.49COMPARE
ACAD$29.11COMPARE
DYN$25.07COMPARE
CELC$88.44COMPARE
RARE$25.61COMPARE